A medicinal product for the local treatment of acute inflammatory diseases of the oral cavity and throat: gingivitis, ulcerative and aphthous stomatitis, tonsillitis, laryngitis, and pharyngitis.
Amilar® IC may be used in cases of mixed infections of the mouth and throat (as recommended by a physician); as an adjunct therapy in the treatment of catarrhal angina, lacunar angina, and Plaut–Vincent angina; and in cases of oral and pharyngeal candidiasis.
It is recommended for use in the postoperative period following tonsillectomy and tooth extraction.
Amilar® IC is also recommended for use in the presence of unpleasant breath odor.
Trade name: Amilar® IC
INN: dequalinium chloride, dibucaine hydrochloride (dequalinium, dibucaine)
Dosage form: lozenges with orange flavor; lozenges with cherry flavor
Pharmacotherapeutic group: throat preparations. ATC code R02A
Registration numbers: UA/14891/01/01; UA/14892/01/01; UA/14893/01/01
Date of registration / valid until: the marketing authorization is valid indefinitely as of 09.09.2020
Packaging: 8 tablets per blister; 1 or 2 blisters per carton
Shelf life: 3 years
Dispensing category: over-the-counter
Search